AOD-9604 vs 5-Amino-1MQ: Two Very Different Routes Into Fat Metabolism Research

Most compounds studied for fat metabolism work on appetite. They make the brain feel full, or slow the stomach, so less energy comes in. AOD-9604 and 5-Amino-1MQ are interesting precisely because neither of them does that. Both were studied for their effects inside the body’s fat and muscle tissue, not on hunger. And yet they could hardly be more different: one is a small fragment cut from growth hormone, the other is not a peptide at all but a small molecule that blocks a single enzyme.

Researchers interested in fat metabolism come across both names constantly, and they are often mentioned in the same breath. This guide explains what each one is, how each is thought to work, what the published studies actually found and where the evidence stops. AOD-9604 and 5-Amino-1MQ are supplied by Crown Peptides strictly for laboratory research use only, and everything below is written for readers interested in the science.

Two Questions About Fat, Two Different Answers

A fat cell has two basic jobs: storing energy as fat when there is extra, and releasing it when the body needs fuel. Research compounds that target fat directly usually try to change the balance between those jobs.

AOD-9604 comes at the problem from the hormone side. Growth hormone is known to encourage fat cells to release fat, a process called lipolysis. AOD-9604 is an attempt to keep that fat-releasing effect while leaving out everything else growth hormone does.

5-Amino-1MQ comes at it from the metabolism side. It blocks an enzyme called NNMT, which is unusually active in the fat tissue of obese animals and people, and which sits at a crossroads of the cell’s energy and methylation chemistry. Blocking it changes how fat cells handle energy from the inside.

So the comparison is not between two versions of the same idea. It is between a hormone signal and an enzyme switch.

Fat research that does not depend on appetite

That point about appetite deserves a closer look. Compounds that act on appetite work through the brain and the gut, and they make animals and people eat less. That is powerful, but it also makes it hard to tell which effects come from eating less and which come from changes inside fat tissue itself. This is the part that makes AOD-9604 and 5-Amino-1MQ so interesting. In the key animal studies of both, food intake did not change. Whatever happened to body fat happened inside the tissues. For researchers who want to study how fat cells store and release energy, without appetite muddying the picture, that is exactly what they need.

AOD-9604: The Piece of Growth Hormone That Burns Fat

Human growth hormone is a large protein of 191 amino acids. In the 1990s, researchers at Monash University in Australia found that a short stretch near its tail end, amino acids 177 to 191, seemed responsible for much of its fat-releasing activity. AOD-9604 is a slightly modified version of that fragment, with an extra tyrosine added to the front, giving a peptide 16 amino acids long. The name stands for Anti-Obesity Drug 9604.

The appeal was obvious. Full growth hormone affects growth, blood sugar and IGF-1 levels, among many other things. A fragment that kept only the fat-releasing part could, in theory, be a cleaner tool.

From a fragment to a drug candidate

The story started with a simple question: which part of growth hormone tells fat cells to stop storing fat? A 1993 study tested the synthetic fragment 177 to 191 on rat fat tissue and found it had the same anti-fat-storage effect as the whole hormone (PMID: 8358331). That pinned the activity to the tail end of the molecule and set the team on the path to a drug.

By 2000, the modified fragment, at that stage called AOD-9401, was being tested by mouth. In genetically obese mice, 30 days of oral treatment slowed weight gain from day 16 onwards, with no change in food intake. Fat tissue from treated mice made less new fat and broke down more stored fat, and the mice burned more energy, glucose and fat. Crucially, the same lipolytic and anti-fat-storage effects appeared in isolated human fat tissue in the lab (PMID: 10950816). That human tissue result is what justified taking the compound into clinical trials.

The mouse studies

A 2001 study in Endocrinology treated obese mice with either human growth hormone or AOD-9604 for 14 days. Both reduced body weight and body fat. Both also raised the levels of beta-3 adrenergic receptors in fat, the main receptors fat cells use to respond to signals to release fat. In obese mice those receptors are suppressed, and both compounds brought them back to levels seen in lean mice (PMID: 11713213).

The same paper ran a revealing control. In mice genetically lacking the beta-3 receptor, long-term treatment no longer produced the weight change, yet a single dose of AOD-9604 still increased energy expenditure and fat burning. The authors concluded that AOD-9604 is not working directly through that receptor, even though it increases it. The exact receptor AOD-9604 acts on is still not settled.

The human trials

AOD-9604 was taken into human trials for obesity by the Australian company Metabolic Pharmaceuticals. Early trials were encouraging, but a larger 24-week trial reported in 2007 did not show meaningful weight loss compared with placebo, and development for obesity was stopped. The compound was generally reported to be well tolerated in those trials. That combination, safe but not effective in people at the doses tested, is the main reason AOD-9604 today is a research compound rather than a medicine.

A second life in cartilage research

AOD-9604 later turned up in a quite different field. In a 2015 study of rabbits with chemically induced knee osteoarthritis, weekly injections of AOD-9604 into the joint improved cartilage scores and shortened the period of lameness compared with saline. Combining it with hyaluronic acid worked better than either alone (PMID: 26275694). That line of research is still small, but it shows the fragment may do more than its name suggests. Our article AOD-9604: the fragment of growth hormone built to do just one of its jobs covers its background in more depth.

5-Amino-1MQ: Switching Off the Enzyme That Helps Fat Cells Grow

5-Amino-1MQ is short for 5-amino-1-methylquinolinium. It is a small, drug-like molecule, not a peptide, and it was designed for one job: blocking nicotinamide N-methyltransferase, usually shortened to NNMT.

Why NNMT matters

NNMT takes nicotinamide, a form of vitamin B3, and attaches a methyl group to it, using up a molecule called SAM in the process. That one reaction touches two important systems. Nicotinamide is the raw material the cell recycles to make NAD+, a molecule central to energy metabolism. SAM is the cell’s main supply of methyl groups, used to switch genes on and off. When NNMT is very active, it drains both.

The key discovery came in 2014. A study in Nature reported that NNMT levels are raised in the fat of obese and diabetic mice, and that reducing NNMT in fat and liver protected mice against diet-induced obesity. Those mice used more energy and gained less fat (PMID: 24717514). That made NNMT a target, and 5-Amino-1MQ is one of the inhibitors designed to hit it.

A small molecule among peptides

5-Amino-1MQ is unusual in this comparison because it is not a peptide at all. It is a small methylquinolinium compound, many times smaller than AOD-9604. That size matters. NNMT sits inside the cell, in the cytoplasm, so an inhibitor has to cross the cell membrane to reach it. The team that developed 5-Amino-1MQ selected it from a series of related compounds partly because it showed good ability to get into cells, which is what turned a potent enzyme blocker on paper into one that worked in living fat cells and in mice. It is a reminder that in metabolic research, the most interesting tools are not always peptides, and that the best comparisons often cross that line.

The obese mouse study

A 2018 study in Biochemical Pharmacology developed a series of NNMT inhibitors based on the methylquinolinium structure and tested a potent one in mice made obese on a high-fat diet. In fat cells grown in the lab, the inhibitors lowered the product of the NNMT reaction, raised NAD+ and SAM inside the cells, and reduced fat production. In the obese mice, treatment reduced body weight and white fat mass, shrank fat cells and lowered total cholesterol. Importantly, food intake did not change (PMID: 29155147).

Fatty liver and blood sugar

The most detailed study of 5-Amino-1MQ itself was published in 2024 in Diabetes, Obesity and Metabolism. Diet-induced obese mice received the compound daily for 28 days. It limited weight and fat gain in a dose-dependent way, improved glucose tolerance and insulin sensitivity, and brought down the high insulin levels typical of obesity. The livers of treated mice had less fat and less inflammation, were smaller and contained less triglyceride, and blood markers of liver damage returned to normal. The researchers also measured where the compound went: after injection under the skin, it reached high levels in the blood and distributed well into fat, muscle and liver, the tissues that matter most for metabolism (PMID: 39161060).

Diet plus NNMT inhibition

A 2022 study asked what happens when NNMT inhibition is combined with a change of diet. Obese mice switched to a low-fat diet lost weight, as expected, but did not get back to the body composition of lean mice in the time studied. Mice switched to the same diet while also receiving 5-Amino-1MQ lost fat and weight dramatically and quickly returned to the measures of age-matched lean animals (PMID: 35013352). That combination result is one of the most striking in the NNMT literature.

Ageing muscle

The same research group then turned to muscle. NNMT also rises with age in skeletal muscle, and it has been linked to poorer muscle stem cell function. In 24-month-old mice with an injured leg muscle, an NNMT inhibitor increased muscle stem cell activity and led to nearly twice the muscle fibre size after recovery compared with untreated mice (PMID: 30753815). There are no published human trials of 5-Amino-1MQ. Our article 5-Amino-1MQ: blocking the enzyme that tells fat cells to store explains the NNMT story in more detail.

Exercise, amplified

The ageing-muscle work went further in 2024. Mice were treated from 22 to 24 months of age, which is old for a mouse, with an NNMT inhibitor, an intensive exercise programme, or both. Sedentary mice given the inhibitor ended up with about 40% greater grip strength than untreated sedentary mice. Exercise alone gave about 20%. The two effects added up, with treated exercising mice reaching a 60% increase (PMID: 38969654). Results like these are why NNMT has become one of the most closely watched targets in metabolic and ageing research.

AOD-9604 vs 5-Amino-1MQ: Side by Side

What kind of molecule?

AOD-9604 is a 16-amino-acid peptide derived from human growth hormone. 5-Amino-1MQ is a small synthetic molecule with no amino acids at all. That difference shapes how each is made, stored and studied.

What does each target?

AOD-9604 acts as a signal on fat cells, mimicking the fat-releasing action of growth hormone through a receptor that is still being identified. 5-Amino-1MQ blocks an enzyme, NNMT, inside cells, which changes their energy and methylation chemistry.

Does either affect appetite?

In the key animal studies, neither worked mainly through eating less. The 2018 NNMT inhibitor study specifically reported no change in food intake.

What is the human record?

AOD-9604 reached human trials and was found to be well tolerated, but it did not produce meaningful weight loss over placebo in the larger trial. 5-Amino-1MQ has not been tested in published human trials.

Where else is each studied?

AOD-9604 has a small body of cartilage and joint research. 5-Amino-1MQ has been studied in ageing muscle and its stem cells.

Which One Fits a Research Question?

When AOD-9604 fits

AOD-9604 suits questions about how growth hormone’s fat-releasing action can be separated from its other effects, and how fat cells respond to that signal, including the beta-3 receptor findings. Its human safety data from the obesity trials gives researchers a reference point that many research peptides lack. It is also a candidate for joint and cartilage work.

When 5-Amino-1MQ fits

5-Amino-1MQ suits questions about cellular metabolism: how NNMT activity affects NAD+ and SAM, how that changes fat storage and energy use, and how the same enzyme influences ageing muscle. Because it is a small molecule rather than a peptide, it also suits studies where stability in solution and cell permeability matter.

Why they are studied together

Because they work through unrelated mechanisms, one on a hormone signal and one on an enzyme, they can be combined in a study without either one masking the other. That is the logic behind the Metabolic Research Bundle, which pairs both with MOTS-c. We explain the reasoning in three compounds, one metabolic pathway.

The Technical Breakdown: A Hormone Fragment and an Enzyme Inhibitor

This section is for readers who want the chemistry.

AOD-9604’s structure

AOD-9604 corresponds to residues 177 to 191 of human growth hormone, with an added N-terminal tyrosine. That region of growth hormone contains a disulphide bond between two cysteines, which forms a small loop thought to be important for its activity. Because the fragment lacks the parts of growth hormone that bind the growth hormone receptor, it does not raise IGF-1 the way the full hormone does, which is central to why it was developed.

5-Amino-1MQ’s structure

5-Amino-1MQ is built on a quinoline ring, a flat, two-ring structure common in drug design, with a methyl group on the ring nitrogen (giving it a permanent positive charge) and an amino group at position 5. That shape mimics part of nicotinamide, letting it sit in NNMT’s binding pocket and block the enzyme. The 2018 study reported that compounds from this family were highly selective, not inhibiting related methyltransferase enzymes or the enzymes of the NAD+ recycling pathway.

How NNMT inhibition raises NAD+

Cells recycle nicotinamide back into NAD+ through what is called the salvage pathway. NNMT competes for the same nicotinamide and, once it has methylated it, that molecule can no longer be recycled. Blocking NNMT leaves more nicotinamide available for salvage, which is why the 2018 study saw NAD+ rise inside fat cells. It also stops SAM being used up, preserving the cell’s methyl supply.

Why AOD-9604’s receptor is still debated

The 2001 knockout result showed that AOD-9604 can still raise energy expenditure without the beta-3 adrenergic receptor, even though long-term weight effects needed it. That suggests more than one mechanism, possibly a direct signal to fat cells plus slower changes in how responsive they are. Identifying the direct target is still an open question.

Why Purity Matters for Both

For AOD-9604, the critical quality points are its full 16-residue sequence and its disulphide loop. A peptide with a missing residue or a broken loop could look similar on a crude test but behave differently. For 5-Amino-1MQ, the concern is chemical purity rather than sequence: closely related quinolinium compounds and leftover synthesis reagents need to be absent, because the compound is often studied at concentrations where small impurities could matter.

How Crown Peptides verifies every batch

Every batch of AOD-9604 Research Peptide and 5-Amino-1MQ Research Compound is tested by HPLC for purity and mass spectrometry for identity. Certificates are published on our Lab Reports page, and our guide on how to read a peptide certificate of analysis explains what each section means. See our storage information for handling.

Handling in the lab

The two compounds bring different quality questions. AOD-9604 contains a small ring, a disulphide bond joining two cysteines in the chain, and mass spectrometry confirms that the ring is correctly closed, because a closed ring and an open one differ in mass. 5-Amino-1MQ is a small molecule rather than a peptide, so HPLC is the main check that no related impurities are present. The peptide is the more delicate of the two to keep. Lyophilised powders are at their most stable when kept cold, dry and away from light, so they should go into the fridge or freezer as soon as they arrive. Once a vial has been reconstituted, it should be kept refrigerated, drawn from with clean technique and used within the window set out in our peptide reconstitution guide. Repeated freezing and thawing of a solution is best avoided, because each cycle gives the chain another chance to break down or clump. Small habits like these protect the purity that the certificate describes, all the way from the vial to the experiment.

Related Compounds in Metabolic Research

NAD+

Since 5-Amino-1MQ works partly by raising NAD+ inside cells, NAD+ itself is a natural comparison. Our NAD+ research guide covers its role in cellular energy.

MOTS-c

MOTS-c is a peptide encoded by mitochondrial DNA and studied for how muscle handles glucose. It approaches metabolism from the energy-use side. See our MOTS-c research guide.

L-Carnitine

L-Carnitine carries fatty acids into mitochondria to be burned, the step that follows fat release. Our article on L-Carnitine and mitochondrial fuel explains why it matters.

For a wider view, see best peptides for weight loss research.

AOD-9604 and 5-Amino-1MQ Questions, Answered

Is 5-Amino-1MQ a peptide?

No. It is a small synthetic molecule built on a quinoline ring. It is often sold alongside peptides and studied in the same research areas, but it has no amino acids.

Is AOD-9604 the same as growth hormone?

No. It is a 16-amino-acid fragment based on the tail end of the 191-amino-acid growth hormone protein. It lacks the parts that bind the growth hormone receptor, so it does not act like growth hormone on growth or IGF-1.

Do either of them reduce appetite?

Neither is mainly studied as an appetite compound. In the 2018 mouse study of an NNMT inhibitor, food intake did not change even though body weight and fat fell. AOD-9604’s proposed actions are on fat cells themselves.

Has either been tested in people?

AOD-9604 has. It was well tolerated in human trials but did not produce meaningful weight loss over placebo in the larger trial reported in 2007. 5-Amino-1MQ has no published human trials.

Can AOD-9604 and 5-Amino-1MQ be studied together?

Yes. Their mechanisms are unrelated, which makes combined designs straightforward to interpret. They come together in our Metabolic Research Bundle.

Why does food intake matter in these studies?

Because it separates two very different routes to less body fat. If animals eat less, they will lose fat whatever else a compound does. In the key studies of both AOD-9604 and 5-Amino-1MQ, food intake stayed the same, which points to effects inside fat tissue and metabolism rather than appetite.

Are they controlled in the UK?

Neither is listed under the Misuse of Drugs Act, and both can be bought for laboratory research. See are peptides legal in the UK for more.

Where This Research Is Heading

The two compounds sit at very different points in their research lives. AOD-9604 has a long and well-documented history, a human safety record from its trials and a growing second life in joint and cartilage work. The open questions around it are about mechanism: which receptor it really acts through, and whether the fat-releasing domain of growth hormone can be harnessed more effectively in different settings or combinations.

5-Amino-1MQ is at an earlier and arguably more exciting stage. In just a few years, NNMT inhibition has gone from a single knockdown result to a body of animal work covering obesity, insulin sensitivity, fatty liver, muscle stem cells and exercise capacity. Each new study has extended the picture rather than contradicting it. The obvious next questions are how NNMT inhibition interacts with other metabolic approaches, how much of its effect runs through NAD+ and how much through methylation, and whether the impressive results in mice carry over to larger animals.

For laboratory research, that makes the pairing especially useful. AOD-9604 offers a well-characterised hormone-side tool. 5-Amino-1MQ offers a fast-moving enzyme-side tool. Together they cover two of the most interesting routes into fat metabolism that do not depend on appetite at all.

A Signal and a Switch

AOD-9604 and 5-Amino-1MQ are often grouped together, but they ask completely different questions. AOD-9604 is a hormone fragment that asks whether the fat-releasing part of growth hormone can be isolated from the rest. 5-Amino-1MQ is an enzyme blocker that asks what happens when a fat cell stops draining its own energy and methylation supplies. One brings human safety data and a long research history. The other brings some of the most striking animal results in metabolic research right now.

That contrast is what makes them useful side by side. Both AOD-9604 Research Peptide and 5-Amino-1MQ Research Compound are available from Crown Peptides with batch-specific certificates, dispatched from the UK.